Gastrointestinal Medicines · LP-076
Bisacodyl Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-076Gastrointestinal Medicines
- Generic identity
- BisacodylTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-076
- Generic identity
- Bisacodyl
- Presentation
- Tablet
- Catalogue strength
- 5 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Bisacodyl.
- Dosage form: Tablet.
- Catalogue strength / concentration: 5 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Gastrointestinal Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Coating/release design, tablet alteration instructions and dissolution specification.
- Whether antacid/milk timing or other comparator handling instructions apply to the exact Luang product.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
A current DailyMed comparator is explicitly labelled delayed release. That supports the need for a formulation hold; it does not establish LP-076 release character.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg | Tablet | — | Blister 10 x 10 tablets | Do not infer enteric/delayed-release coating from common bisacodyl comparator products. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Bisacodyl is a stimulant laxative used in selected constipation and bowel-preparation contexts. Oral tablets and rectal suppositories differ in administration and timing, and one should not be substituted for the other without appropriate instructions. It is not a general treatment for unexplained abdominal pain. This educational profile does not establish Luang Pharma approved labeling or specify a bowel-preparation regimen. Current national restrictions apply.
Clinical context and therapeutic role
A professional should assess the cause and duration of constipation, diet, hydration, mobility and medicines that may contribute. New persistent constipation, weight loss, rectal bleeding or significant pain may require investigation. Bowel preparation for a procedure follows a specific clinical protocol rather than a generic laxative page. Repeated need for stimulant treatment should prompt review. Children and people with possible obstruction or severe dehydration need particular assessment.
Selected safety context
Abdominal cramps, diarrhoea and nausea can occur. Excessive use can cause dehydration and electrolyte disturbance. Suspected bowel obstruction, severe unexplained abdominal pain or persistent vomiting needs urgent assessment before laxative use. Rectal formulations may cause local discomfort. Some coated oral tablets should not be crushed, and antacids or milk may affect the coating’s intended behavior. Follow the exact product instructions and obtain advice for persistent symptoms or unexpected bleeding.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Bisacodyl — clinical backgroundArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| NHS: Bisacodyl — side effectsArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Bisacodyl delayed-release tablet — external label exampleArchived source classification: US official drug label example | Source revision recorded: Updated 2 July 2026; Archived access check: 2026-09-11 | External comparator explicitly labelled delayed release; not evidence that LP-076 has the same coating or handling instructions. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-076.
Professional enquiries
Request product-specific evidence for LP-076.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.